Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Novo Nordisk's Awiqli, a once-weekly basal insulin icodec, for ...

Catumaxomab, then called Removab, and now reborn with the brand name Korjuny, received a positive opinion for the treatment of malignant ascites from the EMA’s Committee for Medicinal Products for ...

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The ...

Europe's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two vaccines: Fluad (surface antigen, inactivated, adjuvanted) and Flucelvax ...

On October 17, the EMA's Committee for Medicinal Products for Human Use concluded that the Siiltibcy skin test showed favorable results compared with two other diagnostic products. Manufactured by ...

and in the first European countries for second-line ESCC and first- and second-line non-small cell lung cancer (NSCLC); ...

with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated ...